HUTCHMED (China) Limited

NASDAQ:HCM

Drug Manufacturers - Specialty & Generic

Healthcare
$13.99 +1.58%

+$0.16 today

Market cap
$2.44B
Beta
0.37
P/E (TTM)
46.2
EPS (TTM)
$0.05
52W Low $10.01High $19.50

Volume 0.04M

Average 0.04M

HCM Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

HUTCHMED (China) LimitedNASDAQ: HCM

Depreciation & Amortization · Q2 FY2025 · quarter ended Jun 2025

Depreciation & amortization dips below year-ago levels

Q2 FY2025 depreciation & amortization of $3.06M fell 2.1% year over year, behind the +14.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.5% a year.

Context

  • Depreciation & amortization amounted to 2.4% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.1% toward the trailing-twelve-month pace of +14.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2025
$3.06M+0.0% QoQ
Last fiscal yearDec 2025
$13.34M+8.1% YoY
LTMJun 2025
$12.21M+14.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.1%——
1 year+8.1%——
3-year CAGR+15.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
13.34M USD
Year-over-year change
+8.1%
4-year CAGR
+16.7%

Depreciation & Amortization vs competitors

How HCM compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.7% is the 5th highest of 9, against a peer median of +13.5%.
  • Depreciation & amortization amounts to 2.0% of revenue for HCM, versus a peer median of 3.6%.
HCM Competitors
Depreciation & Amortization for HCM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
INCYIncyte CorporationLTM Jun 2026$98.28M USD+8.6%+11.2%1.7%
AAPGAscentage Pharma Group InternationalFY2025CN¥86.48M CNY-7.2%+11.2%15.5%
LEGNLegend Biotech CorporationLTM Sep 2026$50.27M USD+111.9%+16.3%3.7%
GMABGenmab A/SLTM Jun 2026$44M USD—-41.9%1.1%
EXELExelixis, Inc.LTM Jul 2026$28.3M USD-5.0%+11.7%1.2%
ZLABZai Lab LimitedLTM Jun 2026$15.93M USD+21.7%+22.2%3.5%
HCMHUTCHMED (China) LimitedLTM Jun 2025$12.21M USD+14.7%+15.5%2.0%
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M USD+0.0%+18.6%8.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$4.6M USD+18.5%+29.8%2.0%
ANLAdlai Nortye Ltd.LTM Jun 2024$2.04M USD—-11.5%31.4%
Peer median (excluding HCM) —+13.5%+14.0%3.6%

Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(167.04M)(360.39M)100.78M37.73M458.12M
Depreciation & Amortization7.19M8.66M8.21M12.34M13.34M
Deferred Income Tax(115.14M)0(102.76M)00
Stock-Based Compensation41.99M30.59M36.6M21.61M15.29M
Change in Working Capital32.46M58.7M71.15M(62.17M)(61.02M)
Accounts Receivables(35.63M)(14.45M)(21.34M)(41.57M)28.94M
Inventory(16M)(21.21M)4.14M(772K)9.57M
Accounts Payables9.57M29.94M(32.54M)03.02M
Other Working Capital74.53M64.04M120.89M(19.82M)(102.55M)
Other Non-Cash Items(3.68M)(6.17M)105.28M(9.01M)(490.56M)
Operating Cash Flow(204.22M)(268.6M)219.26M497K(64.83M)
Capital Expenditures(16.76M)(36.66M)(32.61M)(17.93M)(14.19M)
Acquisitions (Net)159.12M324K(2.99M)028.07K
Purchases of Investments(1.37B)(1.2B)(1.63B)(1.85B)(2.75B)
Sales of Investments921.36M1.52B1.37B1.77B2.74B
Other Investing Activities930K16.49M29.5M1.28M0
Investing Cash Flow(306.32M)296.59M(291.14M)(96.06M)(29.49M)
Debt Repayment(579.77K)(9.17M)61.71M5.61M6.27M
Common Stock Issued717.32M174K5.09M790K1.58M
Common Stock Repurchased(27.31M)(48.08M)(9.07M)(36.06M)0
Dividends Paid(99.74M)(87.44M)000
Other Financing Activities60.34M61.75M(9.07M)(1M)0
Financing Cash Flow650.03M(82.76M)48.66M(30.67M)7.86M
Effect of Forex Changes2.43M(9.49M)(6.47M)(3.4M)3.83M
Net Change in Cash141.91M(64.26M)(29.69M)(129.63M)(82.63M)
Free Cash Flow(220.98M)(305.26M)186.65M(17.44M)(79.01M)

HUTCHMED (China) Limited

NASDAQ:HCM

Intrinsic Alpha fair value

Locked

Current Price

$13.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.